{"id":5344,"count":2,"description":"Hipogonadismul masculin este definit prin niveluri sc\u0103zute de testosteron confirmate \u2014 testosteronul seric diminea\u021ba < 8,0 nmol\/L \u00een cel pu\u021bin dou\u0103 ocazii, asociat cu simptome caracteristice (oboseal\u0103, libido sc\u0103zut, disfunc\u021bie erectil\u0103, stare depresiv\u0103, pierdere de mas\u0103 muscular\u0103, anemie, pierdere de densitate osoas\u0103). Terapia de \u00eenlocuire cu testosteron (TRT) restabile\u0219te nivelurile fiziologice \u0219i \u00eembun\u0103t\u0103\u021be\u0219te aceste simptome. Alternativele care p\u0103streaz\u0103 fertilitatea (clomifen\/enclomifen\/hCG) evit\u0103 suprima\u021bia testicular\u0103 \u0219i infertilitatea cauzat\u0103 de testosteronul exogen \u2014 relevante pentru b\u0103rba\u021bii tineri care \u00eenc\u0103 doresc copii. Catalogul de Hipogonadism MedsBase include op\u021biunile topice de TRT, furnizate de produc\u0103tori certifica\u021bi WHO-GMP<\/strong>.\n\nGel de testosteron topic.<\/strong> Gel topic de testosteron 1% aplicat zilnic pe pielea curat\u0103 \u0219i uscat\u0103 (umeri, bra\u021be superioare, abdomen) \u2014 de obicei 50\u2013100 mg de gel zilnic, \u00een func\u021bie de nivelul de baz\u0103 \u0219i testosteronul seric \u021bint\u0103. Nivelurile serice stabile sunt atinse \u00een 7\u201314 zile; nivelul minim este verificat la 2\u20134 ore dup\u0103 aplicare sau dup\u0103 24 de ore (\u00een func\u021bie de protocol) pentru a confirma \u00eenlocuirea adecvat\u0103. Disponibil sub form\u0103 de Androtas Gel 75 g<\/a> \u0219i Androtas Gel 5 g<\/a>.\n\nPrecau\u021bii de aplicare \u0219i contact.<\/strong> Aplica\u021bi o dat\u0103 pe zi, l\u0103sa\u021bi s\u0103 se usuce 5\u201310 minute, sp\u0103la\u021bi bine m\u00e2inile. Acoperi\u021bi zona de aplicare pentru a evita transferul piel\u0103-pe-piele c\u0103tre femei sau copii \u2014 transferul accidental c\u0103tre femei poate cauza virilizare; transferul c\u0103tre copii poate cauza pubertate precoce\u0103. Evita\u021bi \u00eenotul sau du\u0219ul timp de 4\u20136 ore dup\u0103 aplicare.\n\nAlternative de conservare a fertilit\u0103\u021bii \u2014 consulta\u021bi categoriile conexe.<\/strong> B\u0103rba\u021bii mai tineri care \u00eenc\u0103 doresc copii ar trebui s\u0103 ia \u00een considerare hCG (HUCOG, Puretrig, Eutrig HP \u2014 consulta\u021bi categoria noastr\u0103) sau clomifen \/ enclomifen (Clomiford, Clomisign, Enclomisign) \u00een loc de TRT \u2014 acestea stimuleaz\u0103 produc\u021bia endogen\u0103 de testosteron f\u0103r\u0103 a inhiba func\u021bia testicular\u0103 \u0219i spermatogeneza. Suplimente pentru fertilitate masculin\u0103<\/a> TRT este potrivit doar pentru hipogonadism documentat cu testosteron sc\u0103zut confirmat \u0219i simptome caracteristice \u2014 nu pentru testosteron \u00een limite normale cu simptome nespecifice sau pentru \u00eembun\u0103t\u0103\u021birea performan\u021bei. Evaluarea ini\u021bial\u0103 \u00eenainte de \u00eencepere: testosteron seric (diminea\u021ba, \u00een stare de post, ideal repetat \u00eentr-o alt\u0103 zi), LH\/FSH (pentru a distinge hipogonadismul primar de cel secundar), prolactin\u0103 (exclude prolactinomul), PSA (valoare de baz\u0103), hematocrit (TRT cre\u0219te Hct \u2014 risc de policitemie), scanare DEXA \u00een cazuri selectate. Monitorizare: nivelul de testosteron + Hct + PSA la 3 \u0219i 6 luni, apoi anual. Contraindica\u021bii: cancer de prostat\u0103 (activ sau tratat \u00een ultimii 5 ani), cancer de s\u00e2n la b\u0103rba\u021bi, apnee sever\u0103 de somn netratat\u0103, insuficien\u021b\u0103 cardiac\u0103 necontrolat\u0103, policitemie (Hct > 54%), planificare a paternit\u0103\u021bii (folosi\u021bi hCG \/ clomifen \u00een schimb). Semnalele de siguran\u021b\u0103 cardiovascular\u0103 din studiile mai vechi au fost lini\u0219titoare \u00een meta-analizele recente \u2014 dar discuta\u021bi riscurile cu endocrinologul dumneavoastr\u0103.\n\nImportant.<\/strong> TRT is appropriate only for documented hypogonadism with confirmed low testosterone and characteristic symptoms \u2014 not for normal-range testosterone with non-specific symptoms or for performance enhancement. Baseline assessment before starting: serum testosterone (morning, fasting, ideally repeated on a separate day), LH\/FSH (to distinguish primary from secondary hypogonadism), prolactin (rules out prolactinoma), PSA (baseline), haematocrit (TRT raises Hct \u2014 risk of polycythaemia), DEXA scan in selected cases. Monitoring: testosterone level + Hct + PSA at 3 and 6 months then annually. Contraindications: prostate cancer (active or treated within 5 years), male breast cancer, severe untreated sleep apnoea, uncontrolled heart failure, polycythaemia (Hct > 54%), planning fatherhood (use hCG \/ clomiphene instead). Cardiovascular safety signals from older studies were reassuring on more recent meta-analysis \u2014 but discuss risks with your endocrinologist.\n\nAll MedsBase Hypogonadism products ship from produc\u0103tori certifica\u021bi WHO-GMP<\/strong> cu ambalaj discret \u0219i sunt acoperite de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>.","link":"https:\/\/medsbase.com\/ro\/hypogonadism\/","name":"Hipogonadism","slug":"hypogonadism","taxonomy":"product_cat","parent":3142,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/5344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3142"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product?product_cat=5344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}